直 Japanese PDF Font
  • 我们的专业人员
  • 服务
  • 我们的见解
  • 办公室
  • 事务所
  • 人才招聘
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • 生命科学
    • Transportation and Logistics
  • 经验

医疗设备与诊断

About

医疗设备与诊断 是本所业务分支,下属于 生命科学.

利用创新改善医疗服务和患者生活质量

飞翰与各种规模的创新企业合作,包括财富100强、全球1000强企业及医疗设备与诊断领域的初创公司。挽救生命、提高患者生活质量、改进医疗服务、创造微创性的疾病诊疗方法是医疗设备行业所考虑的首要问题。竞争激烈的诊断领域寻求以更快速精准的结果改进测试,并开发新方法来检测发展中的目标。创新者必须应对极易引起诉讼的专利环境、压缩的利润空间、较短的产品周期和补助方案等方面的挑战,这些都会影响产品的生存能力以及昂贵研发活动(常常需要漫长临床试验)。此外,新设备必须遵守食品药品管理局在安全性和市场营销方面的监管规定,这些规定可能会要求在设备上市之前公开披露敏感技术。为保持竞争优势,公司须最大限度地保护和运用其知识产权。

精通法律、科学与技术

飞翰拥有丰富的法律经验和技术专长,协助客户解决在开发、保护和商业化医疗设备和诊断发明过程中出现的诸多问题。我们的经验包括在申办、尽职调查、专利许可、高风险诉讼方面与大型企业的内部法律顾问合作,向初创企业的高级管理层提供确保其业务不断进展的战略商业建议。我们了解医疗设备行业的竞争颇为激烈,也深知投资者和股东实现价值的迫切愿望,而这些都要求尽早、尽可能有效地保护知识产权。我们还帮助客户应对复杂且不断发展的专利法,这些法律给诊断发明的保护提出了挑战。

从调研新产品的竞争态势到制定有效的诉讼策略,我们提供一系列全面的服务:

  • 由经验丰富的审判和上诉团队在地区法院和上诉法院为高价值产品代理诉讼;
  • 开发和执行诉讼策略,保护客户产品并分析竞争对手产品,从而确保客户顺利实现其知识产权价值;
  • 提供建议并参与授权后程序,包括双方重审和复审;
  • 分析竞争对手专利的价值;
  • 准备和洽谈许可事宜及其他实现知识产权商业化的交易;
  • 就最大限度地减少专利障碍提供咨询;
  • 对兼并和收购对象进行尽职调查;
  • 提供商标申办和咨询。

我们与诸多学科和技术领域的医疗设备客户合作,包括:

  • 糖尿和血糖自测
  • 数字信号处理
  • 施药系统
  • 药物洗脱心脏支架
  • 电子医疗设备
  • 内窥镜检查和泌尿学/妇科系统
  • 介入性心脏病学设备
  • 医疗用品
  • 监测设备
  • 骨科
  • 手术器械
  • 治疗设备

我们与诸多学科和技术领域的诊断客户合作,包括:

  • 基因筛检
  • 免疫筛检
  • 光谱法筛检
  • 人工智能筛检
  • 肿瘤诊断
  • 微生物诊断
  • 产前诊断

该行业领域内的专业人员

经验

Utility and design patent applications for brain machine interface company

Finnegan represents BrainCo, a developer of brain-machine interface (BMI) wearables that combine electroencephalography (EEG) signal processing with artificial intelligence (AI) and machine learning (ML) to enable users to control electronic devices using brain signals. The firm works with BrainCo to develop and implement its intellectual property strategy, including drafting and prosecuting utility and design patent applications, in support of the company’s efforts to build a robust patent portfolio covering innovations and designs related to BMI technologies used in toys, smart home appliances, and robotic devices.

In re Lumify

Successfully represented Bausch & Lomb and Eye Therapies in a Hatch-Waxman patent infringement litigation and parallel PTAB challenges concerning an ANDA for generic versions of over-the-counter Lumify® ocular drops. The cases settled favorably for our clients. 

3:21-cv-16766, D.N.J., Judges Kirsch, Singh
IPR2022-00146, PTAB, Judges Hulse, New, Pollock
IPR2024-00467, PTAB, Judges Flax, Pollock, Yang
IPR2022-00142, PTAB, Judges Flax, Hulse, New, Pollock

Aerin Medical Inc. et al. v. Neurent Medical Inc. et al.
Representing Aerin Medical Inc. and The Foundry, LLC in a patent infringement case involving medical devices for treating nasal airways. Finnegan is also representing patent owners Aerin Medical Inc. and The Foundry, LLC in a series of inter partes review (IPR) challenges to the asserted patents.

1:23-cv-00756, D. Del., Judge Hall
IPR2024-00275, -00276, -00277, -00278, -00279, -00280, -00282, -00669, PTAB

Bay Materials, LLC v. 3M Company
Representing Bay Materials, LLC in district court patent litigation involving multilayer polymer sheet material used in clear dental aligners.

1:21-cv-01610, D. Del., Judges Andrews, Hall

Auris Health, Inc. v. Intuitive Surgical Operations

Represented Intuitive Surgical Operations on appeals from petitions for inter partes review (IPR) filed by Auris Health, Inc.

21-1473, -1732, -1733, Fed. Cir., Judges Prost, Dyk, Reyna
IPR2019-01173, -01533, -01547, PTAB, Judges Franklin, Hulse, Jenks, Worth, Yang

Medmix Switzerland AG v. Kettenbach GmbH and Co. KG et al.
Represented defendants Kettenbach GmbH and Co. KG, Kettenbach LP and Xinial Systems GmbH and Co. KG in a case brought against the Defendants’ dental products for patent and trademark infringement, as well as false advertising, in the United States. After Defendants obtained a final written decision from the U.S. Patent and Trademark Office (USPTO) finding all asserted patent claims in the case to be unpatentable, the parties settled.

2:21-cv-06613, E.D.N.Y., Judge Reyes

More

专业见解

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: May 2026

June 30, 2026

Federal Circuit IP Blog

Federal Circuit Holds Defend Trade Secrets Act Claim Untimely Filed

June 22, 2026

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

More

近期活动

Conference

31st Annual UMass Chan Research Retreat

October 14-15, 2026

Worcester

新闻

Commentary

Finnegan Taps Partner from Kirkland to Boost IP Team

June 12, 2026

Media Mention

Finnegan Hires Kirkland & Ellis Litigator for London Office

June 8, 2026

Commentary

Finnegan Hires Kirkland Partner as It Eyes UK Growth

June 8, 2026

Press Release

London-Based Life Sciences Litigator Jin Ooi Bolsters Finnegan’s Global IP Litigation Capabilities

June 8, 2026

Award/Ranking

Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award

May 13, 2026

Announcement

Finnegan Partner Ningling Wang Becomes President of Licensing Executives Society International

May 4, 2026

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • 隐私
  • 免责申明
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP